Treatment of Fabry Disease: Established and Emerging Therapies
Pharmaceuticals · 20.02.2023 · 16 (2) · 320
DOI: 10.3390/ph16020320 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceuticals, online erschienen am 20.02.2023. Verfasst von Muhammad Umer und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology, University of Louisville, Louisville, KY 40202, USA. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Fabry disease (FD) is a rare, X-linked inherited disorder of glycosphingolipid metabolism. It leads to the progressive accumulation of globotriaosylceramide within lysosomes due to a deficiency of α-galactosidase A enzyme. It involves multiple organs, predominantly the renal, cardiac, and cerebrovascular systems. Early diagnosis and treatment are critical to prevent progression to irreversible tissue damage and organ failure, and to halt life-threatening complications that can significantly reduce life expectancy. This review will focus on the established and emerging treatment options for FD.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cardiology, University of Louisville, Louisville, KY 40202, USA.
ORCID-Profile: Dinesh K Kalra
Zitieren
APA
Umer, M., & Kalra, D. K. (2023). Treatment of Fabry Disease: Established and Emerging Therapies. Pharmaceuticals, 16(2), 320. https://doi.org/10.3390/ph16020320
Vancouver
Umer M, Kalra DK. Treatment of Fabry Disease: Established and Emerging Therapies. Pharmaceuticals. 2023;16(2):320. doi:10.3390/ph16020320
BibTeX
@article{Umer2023,
author = {Umer, Muhammad and Kalra, Dinesh K},
title = {Treatment of Fabry Disease: Established and Emerging Therapies},
journal = {Pharmaceuticals},
year = {2023},
volume = {16},
number = {2},
pages = {320},
doi = {10.3390/ph16020320}
}
EUVIMED